From Yahoo Finance: 2025-06-20 16:07:00

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks recommended as a buy. RBC Capital lowered the price target for VRTX stock to $420 on slower uptake of their new cystic fibrosis treatment, Alyftrek. The company’s operating margins may be affected by gradual patient conversion from Trikafta. Vertex is known for developing therapies for serious diseases, particularly cystic fibrosis. RBC Capital believes Vertex may need stronger execution to justify its current valuation in the market. Despite concerns, the company’s cystic fibrosis franchise is considered well-insulated from sector headwinds.



Read more at Yahoo Finance: Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake